Business Description
Candel Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1374041093
Total Employee Number:
55Description
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.07 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | -0.6 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -5.5 | |||||
3-Year EPS without NRI Growth Rate | 10.4 | |||||
3-Year FCF Growth Rate | 13.5 | |||||
3-Year Book Growth Rate | -16.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.38 | |||||
9-Day RSI | 56.11 | |||||
14-Day RSI | 58.98 | |||||
3-1 Month Momentum % | 14.43 | |||||
6-1 Month Momentum % | 105.09 | |||||
12-1 Month Momentum % | 97.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.09 | |||||
Quick Ratio | 16.09 | |||||
Cash Ratio | 15.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.8 | |||||
Shareholder Yield % | -14.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -91 | |||||
ROA % | -60.24 | |||||
ROIC % | -1104.76 | |||||
3-Year ROIIC % | 704.01 | |||||
ROC (Joel Greenblatt) % | -2688.79 | |||||
ROCE % | -61.59 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 83.49 | |||||
PB Ratio | 7.81 | |||||
Price-to-Tangible-Book | 7.81 | |||||
EV-to-EBIT | -10.03 | |||||
EV-to-EBITDA | -10.11 | |||||
EV-to-Forward-EBITDA | -18.1 | |||||
EV-to-Forward-Revenue | 9.37 | |||||
EV-to-FCF | -14.66 | |||||
| Price-to-Net-Current-Asset-Value | 8.11 | |||||
| Price-to-Net-Cash | 8.26 | |||||
Earnings Yield (Greenblatt) % | -9.97 | |||||
FCF Yield % | -5.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CADL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Candel Therapeutics Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.41 | ||
| Beta | -0.3488 | ||
| 3-Year Sharpe Ratio | 0.78 | ||
| 3-Year Sortino Ratio | 4.03 | ||
| Volatility % | 60.5 | ||
| 14-Day RSI | 58.98 | ||
| 14-Day ATR ($) | 0.732221 | ||
| 20-Day SMA ($) | 12.389 | ||
| 12-1 Month Momentum % | 97.26 | ||
| 52-Week Range ($) | 4.35 - 14 | ||
| Shares Outstanding (Mil) | 76.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Candel Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Candel Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 70 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-15 09:30 | In 12 days | ||
| Guidance call for 2026 | 2026-09-10 15:20 | In 7 days | ||
| Guidance call for 2026 | 2026-09-09 10:00 | In 6 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 10.68 (-0.28%) | ||
| Canaccord Genuity’s 46th Annual Growth Conference | 2026-08-12 12:00 | 10.65 (+0.66%) | ||
| General meeting for 2026 | 2026-06-23 10:00 | 9.15 (+8.80%) | ||
| Guidance call for 2026 | 2026-06-03 17:30 | 8.42 (-1.17%) | ||
| Guidance call for 2026 | 2026-05-20 10:00 | 7.66 (-0.65%) | ||
| Candel Therapeutics phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) | 2026-05-15 13:00 | 8.91 (-3.05%) |
Show
Entries
Candel Therapeutics Inc Frequently Asked Questions
What is Candel Therapeutics Inc(CADL)'s stock price today?
The current price of CADL is $12.97. The 52 week high of CADL is $14.00 and 52 week low is $4.35.
When is next earnings date of Candel Therapeutics Inc(CADL)?
The next earnings date of Candel Therapeutics Inc(CADL) is 2026-11-13 Est..
Does Candel Therapeutics Inc(CADL) pay dividends? If so, how much?
Candel Therapeutics Inc(CADL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Candel Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers